

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6496461

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.	12/21/2020
RECEIVING PARTY DATA	
Name:	INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Street Address:	13-9, ENOKI-CHO, SUITA-SHI
City:	OSAKA
State/Country:	JAPAN
Postal Code:	564-0053
Name:	SUMITOMO DAINIPPON PHARMA CO., LTD.
Street Address:	6-8, DOSHO-MACHI 2-CHOME, CHUO-KU, OSAKA-SHI
City:	OSAKA
State/Country:	JAPAN
Postal Code:	541-8524
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	10071051
Patent Number:	10206985
Patent Number:	10449144
Patent Number:	10195258
CORRESPONDENCE DATA	
Fax Number:	(703)716-1180
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	703-716-1191
Email:	gbpatent@gbpatent.com
Correspondent Name:	GREENBLUM & BERNSTEIN, P.L.C.
Address Line 1:	1950 ROLAND CLARKE PLACE
Address Line 4:	RESTON, VIRGINIA 20191
ATTORNEY DOCKET NUMBER:	P45215
NAME OF SUBMITTER:	WALTER SCHLAPKOHL

SIGNATURE:	/Walter Schlapkohl/
DATE SIGNED:	01/14/2021
Total Attachments: 2 source=P45215_P45221_P45216_P45218_Assignment#page1.tif source=P45215_P45221_P45216_P45218_Assignment#page2.tif	

ASSIGNMENT

WHEREAS, **INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.**, a Corporation organized and existing under the laws of JAPAN, whose mailing address is 13-9, Enoki-cho, Suita-shi, Osaka 564-0053, JAPAN, hereinafter referred to as the ASSIGNOR, is the sole owner of U.S. Letters Patents listed below (hereinafter referred to collectively as “U.S. Letters Patents”):

U.S. Patent Application No. 14/166,950, now issued as U.S. Patent No. 10,071,051, entitled **WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION** by means of assignment recorded effective September 25, 2020 at Reel 053890 and Frame 0829 of the U.S. Patent and Trademark Office assignment records,

U.S. Patent Application No. 14/166,970, now issued as U.S. Patent No. 10,206,985, entitled **WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION** by means of assignment recorded effective September 25, 2020 at Reel 053890 and Frame 0829 of the U.S. Patent and Trademark Office assignment records,

U.S. Patent Application No. 14/166,932, now issued as U.S. Patent No. 10,449,144, entitled **WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION** by means of assignment recorded effective September 25, 2020 at Reel 053890 and Frame 0829 of the U.S. Patent and Trademark Office assignment records, and

U.S. Patent Application No. 14/166,954, now issued as U.S. Patent No. 10,195,258, entitled **TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION** by means of assignment effective September 25, 2020 at Reel 053890 and Frame 0829 of the U.S. Patent and Trademark Office assignment records,

AND WHEREAS, **INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.**, and **SUMITOMO DAINIPPON PHARMA CO., LTD.**, a Corporation organized and existing under the laws of JAPAN, whose mailing address is 6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8524 JAPAN, hereinafter known as the ASSIGNEES, are desirous of becoming joint owners, and desirous of acquiring an undivided interest in the entire right, title and interest for the United States in and to said U.S. Letters Patents, including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted thereon, including any and all renewals, reissues, reexaminations, and prolongations thereof.

NOW, THIS WITNESSETH that for good and valuable consideration, the receipt whereof is hereby acknowledged, said ASSIGNOR hereby assigns, sells and transfers to said ASSIGNEES, their assigns and legal representatives, the entire and exclusive right, title and interest in and to said U.S. Letters Patents, for the United States including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted therefor and all rights to sue for past and future infringement thereunder, said ASSIGNEES and their assigns and legal representatives to have, hold, exercise and enjoy the said U.S. Letters Patents, including any and all divisions and continuations thereof, and any and all Letters Patent which may be granted thereon, including any

and all renewals, reissues, reexaminations, and prolongations thereof, with all the rights, powers, privileges, and advantages in any ways arising from or pertaining thereto, for and during the term or terms of any and all such Letters Patent when granted, including any and all renewals, reissues, reexaminations, and prolongations thereof, for the use and benefit of said ASSIGNEES and their assigns and legal representatives in as ample and beneficial a manner to all intents and purposes as the said ASSIGNOR might or could have held and enjoyed the same, if this assignment had not been made.

AND said ASSIGNOR hereby agrees to execute all papers necessary to file applications in the United States for said U.S. Letters Patents and to assign the same to said ASSIGNEES, or any assignee acquiring title to said U.S. Letters Patents, and to execute any other papers that may be needed in connection with securing Letters Patent thereon.

AND said ASSIGNOR authorizes and requests the Commissioner of Patents to issue Letters Patent, and on any and all divisions and continuations thereof, to said ASSIGNEES as joint owners, their assigns and legal representatives, in accordance herewith.

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR, on the respective date indicated below.

First Witness (Optional):

Hiroyasu Kageyama
(Name) HIROYASU KAGEYAMA

December 25, 2020
(Date)

Jun-ichi Terai
(Signature)

Jun-ichi TERAJ
(Name)

Representative Director and President
(Title)

INTERNATIONAL INSTITUTE OF
CANCER IMMUNOLOGY, INC.

December 21, 2020
(Date)

Second Witness (Optional):

Kazue Sugiyama
(Name) KAZUE SUGIYAMA

December 25, 2020
(Date)